Washington University School of Medicine Digital Commons@Becker

2011 Device Advice from the FDA

2011 Conferences

2011

The importance of device accountability

Colin P. Derdeyn Washington University School of Medicine in St. Louis

Follow this and additional works at: http://digitalcommons.wustl.edu/hrpoconf devad2011

Recommended Citation

Derdeyn, Colin P., "The importance of device accountability" (2011). 2011 Device Advice from the FDA. Paper 5 Human Research Protection Office, Washington University in St. Louis. http://digitalcommons.wustl.edu/hrpoconf_devad2011/5

This Presentation is brought to you for free and open access by the 2011 Conferences at Digital Commons@Becker. It has been accepted for inclusion in 2011 Device Advice from the FDA by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.



The Importance of Device Accountability

Colin P. Derdeyn, M.D.

Mallinckrodt Institute of Radiology and the

Departments of Neurology and Neurological Surgery





Financial Disclosures

Scientific Advisory Board

- W.L. Gore and Associates
- Pulse Therapeutics. Inc

Research Support

- NINDS



Acknowledgements

Kim Striler RN, MSN, CCRC, Clinical Research Specialist. Division of Cardiology, Washington University School of Medicine



Why are we talking about this?

 Use of commercially available product for an IDE trial - identical device may be on the shelf (sloppy)

 Use of an IDE product outside of the trial (temptation)



Purpose of Device Accountability

- Both misuses create real problems
- Protect the rights, safety and welfare of research subjects and patients by ensuring the control and accountability of investigational devices used in clinical research
- Protect data integrity
 - Safety and efficacy or substantial equivalency cannot be established if study devices not used



Consequences

952 759



DEPARTMENT OF HEALTH & HUMAN SERVICES

Cosmetic Act ("the Act"), 21 U.S.C. 321(h).

Public Health Service

Food and Drug Administration Center for Devices and Radiological Health 2098 Gaither Road Rockville, MD 20850

WARNING LETTER VIA FEDERAL EXPRESS

9500 Euclid Ave. F25 Cleveland OH 44195

APR 1 1 2005

Dear Dr.

The purpose of this Warning Letter is to inform you of the objectionable conditions found during a Food and Drug Administration (FDA) inspection conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January 6-18, 2005, by the conducted at your clinical site from January

The purpose of the inspection was to determine if your activities and procedures relating to your participation in the clinical study entitled """ complied with applicable federal regulations. The products under investigation are devices as that term is defined in section 201(h) of the Federal Food. Drug. and

The FDA conducted the inspection under a program designed to ensure that data and information contained in requests for Investigational Device Exemptions (IDE). Premarket Approval Applications (PMA), and Premarket Notifications [510(k)] are scientifically valid and accurate. The program also ensures that human subjects are protected from undue hazard or risk during the course of scientific investigations.

Freedom of Information Act

Stroke and Cerebrovascular Center

Physicians



Consequences

1. You failed to report the use of non-investigational and in 12 of the subjects as required by FDA regulations and the guidelines set forth by your IRB. Non-investigational and were used during the index procedure for 15 of the subjects enrolled in the study. As of January 6, 2005, the IRB had been notified of the use of non-investigational stents in only 3 of these subjects (and the study).

The protocol deviation procedure of your IRB states that deviations from the investigational plan by the investigator or support personnel should be reported promptly to the IRB. The use of non-investigational stents is a deviation from the investigational plan; this deviation was not reported promptly to the IRB. The IRB was not informed of the use of all of the non-investigational stents in this study until the FDA inspection took place. Examples include the following:

- received commercial/non-investigational conjunction with the during their index procedure. The use of these non-investigational is a protocol deviation that was not reported promptly to the IRB and sponsor.
- b. It is a bound of the subject then received a non-investigational than the right of the subject then received a non-investigational than the right of the subject days after the index procedure. This subject was treated despite meeting an exclusion criterion which excludes those subjects where "there is a planned combination procedure involving either the contra lateral carotid artery, a coronary artery, or peripheral artery 30 days before or after the index procedure". These protocol deviations were not reported to the IRB and sponsor as required by your IRB policy and FDA regulations [21 C.F.R. 812.150(a)(4)].

Your written response states that the study coordinator misunderstood the IRB policy, and that the use of these non-investigational was reported to the IRB prior to the completion of the FDA inspection. While this task may be delegated, it is the





Investigator Responsibilities

- Control of the investigational device used in the study
- Ensure the device is stored in a secure area
- Ensure device is used only in patients that consented to participate in the trial
- Ensure device is used according to the IRBapproved protocol
- Ensure records related to the receipt, use and disposition of the device are adequately maintained



Receipt and Inventory

Inventory typically shipped to coordinator
Upon receipt of the investigational device
inventory the shipment, confirm the information
on the packing slip matches the contents
including:

Quantity

Lot numbers

Expiration date

If a discrepancy is noted, contact the sponsor immediately and return any damaged, defective or discrepant devices

File packing slip in the device binder



Device accountability log

Once the inventory is complete and confirmed, enter the data into the device log including:

Date of receipt

Serial and/or lot number

Expiration date

Name or identifiers of person who receives device

Ensure all entries are legible.



Device accountability log

Site Name:	Washington University School of Medicine
Site Number:	1234
Principal Investigator:	Fred Stent, MD

TO THE INVESTIGATOR:

- 1. PLEASE MAINTAIN THIS LOG THROUGHOUT THE STUDY. EACH TEST ARTICLE MUST BE ITEMIZED INDIVIDUALLY BELOW.
- 2. ALL DEVICES RECEIVED BY THE INSTITUTION OR INVESTIGATOR MUST BE ACCOUNTED FOR WHETHER USED OR NOT.
- 3. AT THE COMPLETION OF THE STUDY, PLEASE RETURN ANY UNUSED DEVICES TO THE ADDRESS SHOWN BELOW:

Stent Company

1234 Stent Street

Stent Town, MO 12345

4. AT THE COMPLETION OF THE STUDY, PLEASE KEEP A COPY IN YOUR RECORDS AND RETURN THE ORIGINAL TO The Sponsor

DATE OF RECEIPT (mm/dd/yy) initials	SERIAL NUMBER	Use By Date	SIZE	DEVICE DISPOSITION D = DISCARDED R = RETURNED TO SPONSOR I = Implanted	DISPOSITION DATE (mm/dd/yy) initials	PATIENT STUDY NUMBER	COMMENT (EXPLAIN IF DEVICE WAS DISCARDED, RETURNED TO SPONSOR OR OTHER INCLUDE RGA # AND FED EX #)
1/24/11 KAS	123678	2/22/12	4.0 x 12	□ D □ R □ I □ other		□ N/A	
1/24/11 KAS	155001	6/1/12	3.5 x 16	□ D □ R □ I □ other		□ N/A	
1/24/11 KAS	155332	10/1/11	2.5 x 22	□ D □ R □ I □ other		□ N/A	
				□ D □ R □ I □ other		□ N/A	






Storage of Device

- Store investigational device in a secure location with access limited to the essential research personnel
- Device must be kept in a locked closet or cabinet



Storage of Device



YES





Dispensing Devices

Each time a device is dispensed by the Investigator or a member of the research team, the device log must be updated. This includes:

Device disposition

Date of disposition

Patient study number

Initials of individual dispensing



Dispensing Devices

Site Name: Washington University School of Medicine

Site Number: 1234

Principal Investigator: Fred Stent, MD

TO THE INVESTIGATOR:

- 1. PLEASE MAINTAIN THIS LOG THROUGHOUT THE STUDY. EACH TEST ARTICLE MUST BE ITEMIZED INDIVIDUALLY BELOW.
- 2. ALL DEVICES RECEIVED BY THE INSTITUTION OR INVESTIGATOR MUST BE ACCOUNTED FOR WHETHER USED OR NOT.
- 3. AT THE COMPLETION OF THE STUDY, PLEASE RETURN ANY UNUSED DEVICES TO THE ADDRESS SHOWN BELOW:

Stent Company

1234 Stent Street

Stent Town, MO 12345

4. AT THE COMPLETION OF THE STUDY, PLEASE KEEP A COPY IN YOUR RECORDS AND RETURN THE ORIGINAL TO The Sponsor

DATE OF RECEIPT (mm/dd/yy) initials	SERIAL NUMBER	Use By Date	SIZE	DEVICE DISPOSITION D = DISCARDED R = RETURNED TO SPONSOR I = Implanted	DISPOSITION DATE (mm/dd/yy) initials	PATIENT STUDY NUMBER	COMMENT (EXPLAIN IF DEVICE WAS DISCARDED, RETURNED TO SPONSOR OR OTHER INCLUDE RGA # AND FED EX #)
1/24/11 KAS	123678	2/22/12	4.0 x 12	□ D □ R X I □ other	1/26/11 KAS	□ N/A 1234-001	
1/24/11 KAS	155001	6/1/12	3.5 x 16	□ D □ R X I □ other	1/27/11 KAS	□ N/A 1234-002	
1/24/11 KAS	155332	10/1/11	2.5 x 22	□ D □ R □ I □ other		□ N/A	
				□ D □ R □ I □ other		□ N/A	





Dispensing Devices

SPONSOR: STENT Company

TRIAL NAME: The New Stent Trial

Device: New Stent

Device Accountability Log Page 1 of

Site Name:

Washington University School of Medicine

Site Number:

Principal Investigator:

Fred Stent, MD

TO THE INVESTIGATOR:

- 1. PLEASE MAINTAIN THIS LOG THROUGHOUT THE STUDY. EACH TEST ARTICLE MUST BE ITEMIZED INDIVIDUALLY BELOW.
- 2. ALL DEVICES RECEIVED BY THE INSTITUTION OR INVESTIGATOR MUST BE ACCOUNTED FOR WHETHER USED OR NOT.
- 3. AT THE COMPLETION OF THE STUDY, PLEASE RETURN ANY UNUSED DEVICES TO THE ADDRESS SHOWN BELOW:

Stent Company

1234 Stent Street

Stent Town, MO 12345

4. AT THE COMPLETION OF THE STUDY, PLEASE KEEP A COPY IN YOUR RECORDS AND RETURN THE ORIGINAL TO The Sponsor

DATE OF RECEIPT (mm/dd/yy) initials	SERIAL NUMBER	Use By Date	SIZE	DEVICE DISPOSITION D = DISCARDED R = RETURNED TO SPONSOR I = Implanted	DISPOSITION DATE (mm/dd/yy) Initials	PATIENT STUDY NUMBER	COMMENT (EXPLAIN IF DEVICE WAS DISCARDED, RETURNED TO SPONSOR OR OTHER INCLUDE RGA # AND FED EX #)
1/0/11	1368A	1/4/23	D 23 □ 26	□ D □ R ⊅ J □ other	1/26/11	123-y-00	
	13861		□ 23 ☑ 26	□ D □ R 図 I □ Other	1 .	1234-002	
	14/2/2		□ 23 □ 26	□ D 対 R □ i □ other		□ N/A	Retired
V	19864		□ 23 □ ₃ 26	`Д D R I Other		□ N/A	

^{*}If discarded, returned to sponsor or other, please explain in the comment section





Return or Disposal of Device

- Unused devices will be returned to the sponsor at the end of the trial or if they expire
- Contact the sponsor to obtain a RGA # (returned goods authorization number)
- Log out the devices on the accountability log including the return date and Fed Ex number
- If a device is discarded for any reason, this must also be entered into the device log



Return or Disposal of Device

Site Name:	Washington University School of Medicine
Site Number:	1234
Principal Investigator:	Fred Stent, MD

TO THE INVESTIGATOR:

- 1. PLEASE MAINTAIN THIS LOG THROUGHOUT THE STUDY. EACH TEST ARTICLE MUST BE ITEMIZED INDIVIDUALLY BELOW.
- 2. ALL DEVICES RECEIVED BY THE INSTITUTION OR INVESTIGATOR MUST BE ACCOUNTED FOR WHETHER USED OR NOT.
- 3. AT THE COMPLETION OF THE STUDY, PLEASE RETURN ANY UNUSED DEVICES TO THE ADDRESS SHOWN BELOW:

Stent Company

1234 Stent Street

Stent Town, MO 12345

4. AT THE COMPLETION OF THE STUDY, PLEASE KEEP A COPY IN YOUR RECORDS AND RETURN THE ORIGINAL TO The Sponsor

DATE OF RECEIPT (mm/dd/yy) initials	SERIAL NUMBER	Use By Date	SIZE	DEVICE DISPOSITION D = DISCARDED R = RETURNED TO SPONSOR I = Implanted	DISPOSITION DATE (mm/dd/yy) initials	PATIENT STUDY NUMBER	COMMENT (EXPLAIN IF DEVICE WAS DISCARDED, RETURNED TO SPONSOR OR OTHER INCLUDE RGA # AND FED EX #)
1/24/11 KAS	123678	2/22/12	4.0 x 12	□ D □ R X I □ other	1/26/11 KAS	□ N/A 1234-001	
1/24/11 KAS	155001	6/1/12	3.5 x 16	☐ D ☐ R X I ☐ other	1/27/11 KAS	□ N/A 1234-002	
1/24/11 KAS	155332	10/1/11	2.5 x 22	☐ D XR ☐ I ☐ other	2/1/11 KAS	X N/A	Returned to sponsor, end of study RGA # 12556788 Fed Ex # 123456789-00
				X D □ R □ I □ other	1/27/11 KAS	X N/A	Device opened, contaminated, unused and discarded in the trash





Investigator Responsibilities

- Control of the investigational device used in the study
- Ensure the device is stored in a secure area
- Ensure device is used only in patients that consented to participate in the trial
- Ensure device is used according to the IRBapproved protocol
- Ensure records related to the receipt, use and disposition of the device are adequately maintained



